CollaGenex Pharmaceuticals Appoints Douglas A. Poedtke As Vice President of Sales

CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced today the appointment of Douglas A. Poedtke to vice president of sales. Mr. Poedtke will lead the expansion of the company’s sales force in preparation for the anticipated launch of Oracea, the company’s lead compound for the treatment of rosacea. CollaGenex filed a New Drug Application with the FDA on August 1, 2005 and anticipates a launch of Oracea in the third quarter of 2006.

Mr. Poedtke brings to CollaGenex more than 20 years of strong leadership experience in pharmaceutical product sales to the dermatology market. Most recently, he was vice president of sales for Stiefel Laboratories, an independent pharmaceutical company specializing in dermatology. Prior to joining Stiefel, Mr. Poedtke had a successful career spanning 17 years at Dermik Laboratories, the U.S. dermatology business of the Sanofi-Aventis Group, where he began as a professional sales representative and was successively promoted to the top sales management position in this company. Mr. Poedtke earned his Bachelor of Science in Business Administration from Xavier University.

“We are very pleased to welcome Doug to CollaGenex’s management team as we continue to make significant progress in executing our plan to build a leading dermatology company,” commented Colin W. Stewart, president and chief executive officer of CollaGenex. “Doug’s experience in building and managing top-tier dermatology sales forces will prove extremely valuable as we prepare for the anticipated launch of Oracea in the second half of 2006.”

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company that has built its reputation on providing innovative medical therapies to the dental and dermatology markets. CollaGenex’s professional dermatology sales force markets Pandel(R), a prescription topical corticosteroid licensed from Altana, Inc., Alcortin(TM) (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort(TM) (2% hydrocortisone acetate and 1% pramoxine HCl). Alcortin and Novacort are marketed by the Company under an agreement with Primus Pharmaceuticals Inc. CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that destroy periodontal support tissues and by enhancing bone protein synthesis, and Atridox(R), Atrisorb FreeFlow(R) and Atrisorb-D FreeFlow(R), which are products of QLT, Inc., the successor to Atrix Laboratories, Inc., for the treatment of adult periodontitis.

Research has shown that certain tetracyclines can be chemically modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues. CollaGenex is evaluating various chemically modified tetracyclines (so called “IMPACS” compounds because they are Inhibitors of Multiple Proteases And Cytokines) to assess whether they are safe and effective in these applications. The Company has a pipeline of innovative product candidates with possible applications in dermatology and other disease states. In addition, CollaGenex has acquired the Restoraderm technology, a unique, proprietary dermal drug delivery system, and plans to develop a range of topical dermatological products with enhanced pharmacologic and cosmetic properties.

To receive additional information on the Company, please visit our Web site at www.collagenex.com, which does not form part of this press release.

Forward-Looking Statements

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company’s revenue and expenses, future cash position, including the second quarter and for the remainder of 2005, and its future development efforts, including clinical and development programs and the dermatology franchise, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. CollaGenex’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in CollaGenex’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 under the section “Additional Factors That May Affect Future Results” as well as other documents that may be filed by CollaGenex from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding CollaGenex’ expectations, beliefs, intentions, goals strategies, plans or prospects regarding the future and can be identified by forward-looking words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. CollaGenex assumes no obligations to update the information included in this press release.

Periostat(R) and Restoraderm(R) are registered trademarks and IMPACS(TM) and Oracea(TM) are trademarks of CollaGenex Pharmaceuticals, Inc.

All other trade names, trademarks or service marks are the property of their respective owners and are not the property of CollaGenex Pharmaceuticals, Inc. or any of our subsidiaries.

Novacort(TM) and Alcortin(TM) are trademarks of Primus Pharmaceuticals, Inc.

Pandel(R) is a trademark of Taisho Pharmaceuticals.

Atridox(R), Atrisorb(R) and Atrisorb-D(R) are registered trademarks of QLT USA, Inc.